THESIS
2013
xxxiv, 211 p. : ill. (some col.) ; 30 cm
Abstract
Cardiovascular diseases (CVD) are the major causes of mortality and morbidity in general
population. Conventional markers, like low-density lipoprotein (LDL) and C-reactive protein
(CRP) are used for prognosis of CVD. However, the ability of those factors to identify such
patients is limited and the clinical values of them are still questionable. Recently, lipocalin-2
(LCN2), a 25 kDa secretory glycoprotein, has been regarded as a novel biomarker for
cardiovascular risk assessment. It is involved in the pathogenesis of obesity and CVD by
inflammatory process. There is even an evidence showing that LCN2 is a superior
independent biomarker compared to CRP for CVD death prediction.
A simple with high detection range enzyme-linked immunosorbent assay (ELISA) was
developed for quant...[
Read more ]
Cardiovascular diseases (CVD) are the major causes of mortality and morbidity in general
population. Conventional markers, like low-density lipoprotein (LDL) and C-reactive protein
(CRP) are used for prognosis of CVD. However, the ability of those factors to identify such
patients is limited and the clinical values of them are still questionable. Recently, lipocalin-2
(LCN2), a 25 kDa secretory glycoprotein, has been regarded as a novel biomarker for
cardiovascular risk assessment. It is involved in the pathogenesis of obesity and CVD by
inflammatory process. There is even an evidence showing that LCN2 is a superior
independent biomarker compared to CRP for CVD death prediction.
A simple with high detection range enzyme-linked immunosorbent assay (ELISA) was
developed for quantitative detection of LCN2 in serum, plasma and urine. The detection limit
and functional sensitivity are 0.20 and 0.39 μg/L, respectively. A rapid, portable and
user-friendly point-of-care lateral-flow immunoassay was also developed for quantification
of LCN2 in whole blood, serum and plasma. The detection limit and functional sensitivity are
1.5 and 2.0 μg/L, respectively. In order to increase the prognostic performance of CRP, a dual-biomarker lateral-flow immunoassay was invented for simultaneous quantification of
LCN2 and CRP within 15 min.
The prognostic performance of LCN2 was evaluated with obese/diabetic patients, patients
with acute coronary syndrome (ACS) and the control group. Based on the results of ACS
patients and the control group, the LCN2 cut-off value found was 31 μg/L using the in-house
ELISA and 33 μg/L using the developed lateral-flow immunoassay. The diagnostic sensitivity
was 0.75. It was also found that obese/diabetic patients had higher serum LCN2
concentrations than health subjects (P < 0.05). After combining both LCN2 and CRP, the
diagnostic sensitivity of LCN2 increased of from 0.75 to 0.90. Therefore, it is concluded that
LCN2 can be applied for risk stratification of CVD.
Post a Comment